1Pisella P J, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol, 2002,86:418-423.
2Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface changes induced by topical application of latanoprost and timolol: a shortterm study in glaucomatous patients with and without allergic conjunctivitis. Graefe Arch Clin Exp Ophthalmol, 2001,239:809-814.
3Herreras JM, Pastor JC, Calonge M , et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug.Ophthalmology, 1992,99:1082-1088.
4Ihan A, Cvenkel B. Conjunctival epithelium expression of FILA-DR in glaucoma patients and its influence on the outcome of filtration surgery. Br J Ophthalmol, 2000, 84: 648-650.
5Baudouin C, Brignole F, Becquet F, et al. Flow Cytometry in impression cytology specimens. Invest Ophthalmol Vis Sci, 1997,38 :1458-1464.
6Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol, 1995,79:339-342.
7Baudouin C, de Lunardo C. Short-term comparative study of topical 2 % carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthatmol, 1998, 82:39-42.
8Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication I. The conjunctival cell profile. Arch Ophthalmol, 1994, 112: 1437-1445.
9Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and anirnal studies. Ophthalmology, 1999, 106: 556-563.
10Schwab IR, Linberg JV, Gioia VM, et al. Foreshortening of the inferior conjunctival fomix associated with chronic glaucoma medications. Ophthalmology, 1992, 99: 197-202.
